NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether CVS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2024, CVS issued a pr ...

Juanmonino/iStock Unreleased via Getty Images Investment Thesis I'm not sure how many investors currently hold CVS Health Corporation (NYSE:CVS) for the growth or the dividend, but with the recent drop in share price, some may be left wondering if the dividend is secure. As an investor solely investing for dividends to supplement my retirement, this is always my main concern when my portfolio holdings have a bad quarter or year. In this article, I discuss the company's recent earnings, which caused the stoc ...

Is this still a safe dividend stock you can buy and hold for the long haul?Shares of CVS Health (CVS -0.83%) have been under pressure this month after the healthcare giant reported uninspiring quarterly results. It also reduced its guidance for the year. With the company facing higher costs and headwinds due to macroeconomic conditions, investors have grown wary of the stock, and its dividend as well. Now yielding around 4.8% per year, is CVS Health's dividend too high and due for a cut?Can CVS Health affor ...

业绩总结 - 公司对2024年第一季度业绩感到失望，特别是在医疗保险方面，医疗成本线上的高利用率导致了大约9亿美元的差额[7] - 公司预计2024年的每股收益将在7美元左右，主要取决于医疗保险成本趋势和其他因素，如投资收益、费用等[27] - 今年的经营活动现金流预计将超过105亿美元[39] 未来展望 - 公司计划通过调整福利、加强医疗管理和审查网络等方式来弥补2025年的利润率不足，并希望在2025年实现高达200个基点的利润率提升[19] - 公司将重点放在利润率而非会员数量上，计划在2025年实现4%至5%的目标利润率，并将通过调整福利、重新设计产品或退出市场等方式来实现这一目标[24] 新产品和新技术研发 - Cordavis业务推出非常成功，4月份的生物类似药物销售量超过了2023年全年的销售量[46] - CostVantage模式和TrueCost的采用进展顺利，大型PBM合同通常在年底签署[55] 市场扩张和并购 - 公司在健康服务领域的指导降低了约4亿美元，其中一大部分与健康护理交付业务有关，主要是由于ACO REACH业务的问题导致的节省率低于预期[33] 负面信息 - Moody's杠杆率为4倍，公司计划降低至4倍以下[41] 其他新策略和有价值的信息 - CVS积极配合政府对PBM行业的调查，认为自己是市场上唯一有效降低成本的参与者[61] - 针对通货膨胀减缓法案的影响，公司关注药品清单和Part D计划的变化[64] - Part D计划的风险将转移到计划方，可能导致2025年开放报名季节价格大幅上涨[65]

Year to date, shares of CVS are now down by nearly 30%.Shares of CVS Health (CVS 0.25%) have been falling sharply this month after investors were unimpressed with the healthcare giant's latest earnings numbers. The sell-off has been so extreme that not only is CVS trading near its 52-week low, but the stock is now at levels it hasn't been at since 2020. It seems to be trading at a high discount, and with the big decline in price, its dividend is now yielding 4.8%, which is far higher than normal.Is the sell ...

Concerns higher than during COVID-19 pandemic, with the effects of social media a driving factorWOONSOCKET, R.I., May 9, 2024 /PRNewswire/ -- A recent CVS Health® (NYSE: CVS)/Morning Consult survey found that a majority of adults have significant concerns about their mental health and rates across the country continue to rise. Image provided by CVS Health Two-thirds (65%) of adults have experienced concerns about their own mental health or the mental health of their friends and family, which is up six ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about CVS Health (CVS) .CVS Health currently has an average brokerage recommendation (ABR) of 1.98, o ...

文章核心观点 - 保险业务是长期积累财富的好途径 ，推荐三家有望让人成为百万富翁的保险股票 [1][2] 保险行业特点 - 保险是为风险定价 ，是最具抗通胀能力的业务之一 ，成本上升时保费也会增加 [1] - 保险公司有独特的用他人资金投资赚钱的能力 ，保费形成的 “浮存金” 可用于投资并保留利润 [1] 推荐的保险股票 保德信金融（Prudential Financial） - 注重维持坚实的财务基础 ，以直布罗陀岩石为公司标志 ，资产负债表上有超 3200 亿美元债券 ，总净资产超 280 亿美元 [3] - 强大的资产负债表有助于保险公司应对超出预期的理赔 ，让投资者相信其有强大的持久力 [3] 伯克希尔·哈撒韦（Berkshire Hathaway） - 由投资大师沃伦·巴菲特领导 ，几十年来在保险浮存金投资方面表现出色 [5][6] - 除成功的保险业务外 ，还拥有众多子公司 ，并积累了数十亿美元的上市公司投资组合 ，为投资者提供成为百万富翁的强大基础 [6] CVS Health - 以药店网络闻名 ，收购健康保险公司安泰后 ，保险成为重要收入驱动力 [7] - 近期财报不佳致股价下跌 ，但对长期投资者可能是好消息 ，分析师预计 2024 年每股收益 7.40 美元 ，2025 年为 8.22 美元 [7] - 目前估值较低 ，2024 年预期收益约 7.6 倍 ，2025 年约 6.8 倍 ，股息收益率近 4.8% ，有望为耐心投资者带来可观回报 [7] 投资建议 - 实现百万美元投资组合需要时间 ，应尽早开始投资 ，考虑将这些保险股纳入投资组合 [8]

William Farrington - William Farrington是一位经验丰富的研究员和记者，曾在全球法律出版物担任职务，后来转向Proactive Investors，在一家主要的金融科技公司担任记者，专注于加密货币和区块链技术[1] Proactive新闻团队 - Proactive的新闻团队遍布全球主要的金融和投资中心，设有办事处和工作室，包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯[2] Proactive的专业领域 - Proactive是中小市值市场的专家，同时也向社区提供蓝筹公司、大宗商品和更广泛的投资故事的最新信息，激发和吸引有动力的个人投资者[3] Proactive团队的报道范围 - Proactive团队跨越市场提供新闻和独特见解，涵盖生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等领域[4]

股市走势 - S&P 500在5月1日下跌了0.3%，因为美联储保持利率不变，主席杰罗姆·鲍威尔认为即将加息的可能性不大[1] 公司业绩 - CVS股价暴跌，因为这家药店巨头未达到预期并在高医疗成本和医疗保险报销压力下削减了业绩指引[2] - Bio-Techne股价飙升，因为这家生物技术公司发布了超出预期的业绩，受到诊断和基因组领域的强劲支撑[3]